Slide 1 Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Phase III…

Slide 1 Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2 Trial…

Slide 1 Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi at 2014…

Slide 1 Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting Metastatic Cervical Cancer Presented By Christian Hinrichs at 2014 ASCO Annual Meeting Adoptive…

Slide 1 Managing Comorbidities In Oncology: A multisite randomized controlled trial of continuing vs.discontinuing statins in the setting of life-limiting illness Presented…

Slide 1 Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2 Trial…

Slide 1 First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their…

Slide 1 Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy…

Slide 1 Prevention of Early Menopause Study(POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone receptor-negative…

Slide 1 Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Phase III…